Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)
- Status
- COMPLETED
- Phase
- PHASE2
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
- Status
- COMPLETED
- Phase
- PHASE2
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2